We aim to develop disease-modifying therapies for people living with metabolic diseases, including obesity and diabetes. Carmot was acquired by Roche in early 2024.
Modulating core energy homeostatic pathways is critical to addressing this disease burden. Carmot’s clinical pipeline targets two main incretins, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP), both of which play significant roles in energy homeostasis.